GlassScriptPhysician profile
Daniel S Emmett
NPI 1477651982
$16,004.35
in general payments reported to CMS, 2019-2025
41 companies · $2,852 in 2025
The $2,852 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,785 · 2020: $973 · 2021: $1,890 · 2022: $2,310 · 2023: $2,987 · 2024: $3,208 · 2025: $2,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,881 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,881.00 |
| Education | $165.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,063.88 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,632.58 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $1,011.69 | 2021-2024 | Zeposia |
| Pfizer INC. | $873.26 | 2019-2025 | |
| Janssen Biotech, INC. | $787.16 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $779.15 | 2019-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $364.60 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $331.62 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $308.66 | 2019-2024 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $306.81 | 2020-2023 | |
| Celltrion USA INC. | $286.06 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $245.67 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $242.30 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $233.72 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $228.37 | 2024-2025 | Resmetirom, Rezdiffra |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $226.94 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $219.16 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $214.80 | 2021-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $207.01 | 2023-2025 | Omvoh |
| Redhill Biopharma INC. | $199.25 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $178.68 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $166.57 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $157.97 | 2022-2024 | Dificid |
| Medtronic, INC. | $152.46 | 2025 | Interstim |
| Braintree Laboratories, INC. | $113.76 | 2020-2025 | Sutab, Suflave |
| Boston Scientific Corporation | $65.95 | 2021-2023 | Exalt Model D |
| Johnson & Johnson Health Care Systems INC. | $65.76 | 2022 | |
| Organon LLC | $63.22 | 2022-2024 | Renflexis |
| Mauna Kea Technologies, INC. | $50.98 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $47.30 | 2025 | Zenpep |
| Allergan, INC. | $29.94 | 2019 | |
| Vivus LLC | $22.63 | 2024 | Qsymia |
| Ethicon US, LLC | $19.85 | 2019 | |
| Shield Therapeutics INC | $19.68 | 2023 | Accrufer |
| Ferring Pharmaceuticals INC. | $18.99 | 2023 | Rebyota |
| Shire North American Group INC | $16.58 | 2019 | |
| Ucb, INC. | $15.81 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $14.12 | 2021 | |
| Olympus America INC. | $12.70 | 2023 | Evis Exera Lll Colonovideoscope, Evis Exera III Duodenovideoscope |
| Romark Laboratories, Lc | $8.71 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Emmett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.